Abstracts tagged "Upadacitinib"

Abstract Number: 1340 • ACR Convergence 2021
Upadacitinib Effects on Entheseal Domain in Psoriatic Arthritis Patients – a Pooled “post-hoc” Analysis from Two Phase III Studies (Select PsA 1 and 2)
Fabrizio Cantini¹, Antonio Marchesoni², Francesca Marando³, Giuliana Gualberti³, Lucia Novelli³, Giacomo Curradi³, Erin McDearmon-Blondell⁴, Tianming Gao⁵ and Carlo Salvarani⁶, ¹Department of Rheumatology, Azienda USL Toscana Centro, Hospital of Prato, Prato, Italy, ²Dipartimento di Reumatologia, ASST Gaetano Pini-CTO, Milano, Italy, ³AbbVie, Rome, Italy, ⁴AbbVie Inc., Elmhurst, IL, ⁵AbbVie Inc., North Chicago, IL, ⁶Unità Operativa di Reumatologia, Azienda USL-IRCCS di Reggio Emilia, Italy, Reggio Emilia, Italy
Background/Purpose: Reaching control or improvement on enthesitis domain in psoriatic arthritis (PsA) is challenging, and it continues to be a priority for patients (pts) and…
Abstract Number: 509 • 2019 ACR/ARP Annual Meeting
Safety Profile of Upadacitinib in Rheumatoid Arthritis: Integrated Analysis from the SELECT Phase 3 Clinical Program
Stanley Cohen¹, Ronald van Vollenhoven ², Kevin Winthrop ³, Cristiano A. Zerbini ⁴, Yoshiya Tanaka ⁵, Louis Bessette ⁶, Ying Zhang ⁷, Nasser Khan ⁸, Barbara Hendrickson ⁷, Jose Jeffrey Enejosa ⁷ and Gerd Burmester ⁹, ¹Metroplex Clinical Research Center, Dallas, TX, ²Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ³Oregon Health and Science University, Portland, OR, ⁴Centro Paulista de Investigação Clinica, São Paulo, Brazil, ⁵University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ⁶Laval University, Quebec City, QC, Canada, ⁷AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁸Abbvie Inc, North Chicago, IL, ⁹Charité—University Medicine Berlin, Berlin, Germany
Background/Purpose: Upadacitinib (UPA), an oral JAK1-selective inhibitor, was evaluated in a comprehensive clinical program of 5 pivotal Phase 3 randomized-controlled trials (RCTs) across the full…
Abstract Number: 846 • 2019 ACR/ARP Annual Meeting
MACE and VTE Across Multiple Upadacitinib Studies in Rheumatoid Arthritis: Integrated Analysis from the SELECT Phase 3 Clinical Program
Ernest Choy¹, Iain McInnes ², John Cush ³, Jacob Aelion ⁴, Ying Zhang ⁵, Nasser Khan ⁶, Jianzhong Liu ⁶, Heidi Camp ⁷, Sebastian Meerwein ⁸, William Rigby ⁹ and Alexander Cohen ¹⁰, ¹Cardiff University School of Medicine, Cardiff, United Kingdom, ²Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ³5Baylor University Medical Center, Dallas, ⁴Arthritis Clinic PLLC, Jackson, ⁵AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁶Abbvie Inc, North Chicago, IL, ⁷AbbVie Inc., North Chicago, IL, ⁸AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, ⁹Dartmouth-Hitchcock Medical Center, Lebanon, ¹⁰Guy’s and St Thomas’ NHS FT Hospitals, King’s College London, London, United Kingdom
Background/Purpose: Patients (pts) with RA have an approximate 2-fold increased risk of cardiovascular (CV) morbidity and mortality and of venous thromboembolic events (VTE)1,2. Among RA…
Abstract Number: 2907 • 2019 ACR/ARP Annual Meeting
Clinical and Functional Outcomes Among Rheumatoid Arthritis Patients Switching Between JAK1-Selective Inhibitor Upadacitinib and Adalimumab Following Insufficient Response
Roy Fleischmann¹, Mark Genovese ², Ricardo Blanco ³, Stephen Hall ⁴, Glen Thomson ⁵, Filip Van den Bosch ⁶, Cristiano A. Zerbini ⁷, Jose Jeffrey Enejosa ⁸, Yihan Li ⁹, Ryan DeMasi ⁹ and In-Ho Song ⁸, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Stanford University, Stanford, CA, ³Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, ⁴Monash University and Emeritus Research, Melbourne, Australia, ⁵CIADS Research, Winnipeg, Canada, ⁶Ghent University Hospital, Ghent, Belgium, ⁷Centro Paulista de Investigação Clinica, São Paulo, Brazil, ⁸AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁹AbbVie Inc., North Chicago, IL
Background/Purpose: The goal of RA treatment is to achieve clinical remission or, at minimum, low disease activity (LDA). Modification of initial csDMARD therapy with the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].